FAQ

J591 monoclonal antibody

Known as: J591 MAb, Monoclonal Antibody J591, J591 
Monoclonal recombinant antibody J591 (mAb HuJ591) recognizes the extracellular domain of prostate specific membrane antigen (PSMA), a cell surface… (More)

Topic mentions per year

Topic mentions per year

1999-2017
051019992017

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
J591 monoclonal antibody
Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
PURPOSE To assess the efficacy of a single infusion of radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
UNLABELLED (89)Zr (half-life, 78.41 h) is a positron-emitting radionuclide that displays excellent potential for use in the… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
PURPOSE Based on prostate-specific membrane antigen (PSMA) expression on the vasculature of solid tumors, we performed a phase I… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
PURPOSE To determine the maximum tolerated dose (MTD), toxicity, human anti-J591 response, pharmacokinetics (PK), organ dosimetry… (More)
Is this relevant?
2005
2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
UNLABELLED 111In-Labeled antibodies and peptides have been routinely used as chemical and biologic surrogates for 90Y-labeled… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
PURPOSE To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, pharmacokinetics… (More)
Is this relevant?
2004
2004
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.
Targeted therapeutics using antibodies are an attractive option over conventional cancer chemotherapeutics due to their potential… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2000
2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
A novel alpha-particle emitting monoclonal antibody construct targeting the external domain of prostate-specific membrane antigen… (More)
Is this relevant?
2000
2000
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Prostate-specific membrane antigen (PSMA) is a well-characterized cell surface antigen expressed by virtually all prostate… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that was initially characterized by the… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?